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ABSTRACT
Objective: Musculoskeletal disorders and depression are common among migraineurs. The aim of
our study is to evaluate the occurrence of these disorders among working aged migraineurs.
Material and Methods: The risk for fibromyalgia, rheumatoid arthritis (RA), osteoarthrosis (OA),
sciatic syndrome and the occurrence of depression were studied among cases who reported about
these conditions and migraine in working aged Finnish population in The Health and Social
Support Study (HeSSup) based on postal questionnaire in 2012. Group differences were tested by
Chi-square test. Odds ratios (ORs with 95% CI) adjusted for age, gender, education level and
depression were calculated with logistic regression analysis.
Results: Total of 1505 migraineurs (13%) and 8092 controls were included among the 11 596
responders in 2012. Age and gender adjusted OR’s, 2.37 (95% CI 1.81 − 3.09) for fibromyalgia,
1.46 (1.10 − 1.95) for RA, 1.58 (1.38 − 1.80) for OA and 2.09 (1.84 − 2.37) for sciatic syndrome
were significant. At least moderate depression was more common among migraineurs (7.3%) than
among controls (3.4%) (p <0.001).
Conclusion: Recognition of comorbid musculoskeletal disorders and mood disorders among
migraineurs need targeted outreach in working aged population. The acute and preventive
treatments to control for neuronal sensitization in migraine and comorbid pain disorders may
benefit of individual treatment plan and tailored use of antidepressants.
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1 Introduction
Migraine is a common disorder in working aged population and the occurrence peaks in the late
teens and around 50 years of age. [1]  The sociodemographic correlates have been stable for over
50 years and across studies the estimates of the 12-month prevalence yield a total of 18.5%.  [1]
Pathophysiology of migraine is complex [2], including neuroinflammatory mechanisms and both
peripheral and central sensitization. [3] Migraine is among the rare neurological conditions
accompanying fibromyalgia. [4]  The reported comorbidity is high and associates with
anxiety, depression, and insomnia. [5,6] Pathophysiology linking these painful disorders remains
poorly understood; suggested mechanisms include involvement of peripheral and central
sensitization disturbances. [3,7]  Neural sensitization has also been shown in other comorbid
painful conditions in migraine, such as rheumatoid arthritis (RA) and osteoarthritis (OA)  [8,9] .
The aim of our study is to evaluate the occurrence and risk of some comorbid and common painful
musculoskeletal disorders such as fibromyalgia, osteoarthrosis, sciatic syndrome, rheumatoid
arthritis and depression among migraineurs in a working aged population in Finland. The aim is
relevant as depression and the pain conditions under study are reported to be common disabling
conditions in the workforce. [10,11]
Material and methods
Health and Social Support Study
The Health and Social Support Study (HeSSup) is a prospective follow-up study on psychosocial
health of Finnish working-age population. The Turku University Central Hospital Ethics
Committee approved the study. Respondents' permission was also requested to collate the
information with official registers. The questionnaire screens the self-reported health related
factors and disturbances. It includes 33 items and several common disorders among working aged
population. First postal questionnaire was sent in 1998 to a random sample of 64 797 individuals
drawn from the Finnish Population Register, followed by follow-up questionnaires in 2003 and
2012 sent to those responding to the first HeSSup survey, excluding those who had died, moved
abroad or whose present addresses were unknown. According to the non-response analysis in 1998
respondents and non-respondents were comparable with respect to the most important
demographic variables including gender and age distribution [12] and the differences in physical
health between participants and the general population were minor. [12,13]
Algorithm of responder distribution in the three surveys is shown in Figure 1. In 1998 altogether
25 895 responded and the respond rate was 40%. These participants were inquired whether a
doctor had told them they have or have had migraine. Of them 25 691 (99.2%) responded to the
question on migraine.
The International Headache Society International Classification of Headache Disorders criteria for
migraine diagnosis are followed among doctors in Finland. Triptans are used and reimbursed as
acute migraine treatment in Finland from 1993. The registers of The Finnish Social Insurance
Institution (SII) were used to study the prescribed and reimbursed triptan medications between
1998 and 2013. A search for prescribed medications was carried out by linking the HeSSup and
SII registers using the personal identification code given to all Finnish citizens as a key.
The final sample on included cases comprises those individuals who had reported migraine in all
three questionnaires (N=11 596) and they were regarded as migraineurs. The respective control
group includes cases who have responded negatively to all inquiries on migraine (N=8 176). Cases
with triptan prescription in the control group, 84 individuals, were excluded as no self-reported
migraine was recorded. The final control group thus comprised 8 092 individuals.
For the purposes in this survey we focused on following comorbid items in the questionnaire:
painful disorders such as fibromyalgia, RA, OA and sciatic syndrome. We did not include less
common syndromes in our estimates (e.g. myofascial pain syndromes, temporomandibular
disorders) or other musculoskeletal disorders (e.g. traumatic or other neck or back pain).
Respondents were inquired whether a doctor had told them they have or have had these
conditions. Those who reported about these conditions in 2012 were included in the analyses.
Severity or pain score was not assessed.
Beck’s depression inventory (BDI) scores were included and assessed. If a responder scored more
than 18 points in BDI he/she was considered as having at least moderate depression. Information
on marital status and education was collected and assessed as lower or higher according to having
passed the Finnish matriculation examination.
Data were analyzed using the IBM SPSS Statistics version 23. Statistical significances were tested
by chi-square test. Odds ratios (ORs with 95% CI) for migraine as dependent and other painful
disorders as covariates were calculated with separate logistic regression analyses. These analyses
were first calculated with no adjusting (Model 1) and then with adjusting for age and gender
(Model 2). In Model 3 the calculations were made with adjusting for both age and gender and
education (matriculation examination). Finally, in Model 4 the calculations were made with
adjusting for age, gender, education and at least moderate depression (Beck > 18).
Results
Migraine was reported by 1 505 (13%) cases versus the 8 092 cases who did not report migraine
nor had been prescribed for any triptan medication among the included 11 596 responders in 2012.
The female (77.4%) to male ratio was 1228/277 in the migraine group and 4581/3 511 (56.6%) in
the control group. Majority of all migraine cases, 32.2 %, belonged to the oldest and 20.2 % to the
youngest age group. (Table 1.)
The self-reported severity of depression by BDI scores was higher and statistically different
between migraineurs and controls, (p<0.001). The difference in mean scores of BDIs among
migraineurs (7.1 points) and controls (5.4) and at least moderate depression (Beck >18) was
reported by 7.3% and 3.4% respectively (p<0.001). Depression was as common among older and
younger migraineurs. Lower education status was more common among migraineurs but no
difference was observed for the marital status as compared to controls. (Table 1)  Triptans were
prescribed in 522 migraine cases, 34.7%.
All four painful musculoskeletal disorders, fibromyalgia, RA, OA and sciatic syndrome, were
reported more often among migraineurs than among controls. One in three migraineurs reported
sciatic syndrome and OA compared to one in five among controls. (Table 2)
In the two oldest age groups all four reported disorders were more common among female and
also OA among male migraineurs compared to controls. In the two youngest age groups OA,
sciatic syndrome and fibromyalgia among women and sciatic syndrome among men were more
common. Almost half of female and one third of male migraineurs reported OA while the rate in
the younger age groups was only one in ten. (Table 3)
Musculoskeletal disorders reported by migraineurs showed a higher and statistically significant
risk in both univariate and multivariable models. Odds ratio (OR) with 95% CIs in logistics
regression analysis were 2.37 (95% CI 1.81 − 3.09) for fibromyalgia, 1.46 (1.10 − 1.95), for RA,
1.58 (1.38 − 1.80) for OA and 2.09 (1.84 − 2.37) for sciatic syndrome in the age and gender
adjusted Model 2.  In separate logistics regression analyses in Models 3. and 4. adjustment for age,
gender, education and at least moderate depression had only slight influence, the ORs were high
for all four musculoskeletal disorders, and the association with migraine was statistically
significant. (Table 4)
Discussion
The key finding in this study was that several common painful musculoskeletal disorders, such as
rheumatoid arthritis, fibromyalgia, osteoarthrosis and sciatic syndrome were reported significantly
more often in the working aged migraine than in the control population. Migraineurs reported
more often a lower education level and at least moderate depression compared to the controls. The
risk for all four musculoskeletal disorders was high and statistically significant after adjustment
for age and gender, as well as with education and at least moderate depression.
Self-reported migraine is generally considered reliable, and this method is used in several
observational studies.  [14-16] In line with other studies we did not use diagnostic questions to
identify individuals with different pain conditions. We used recall prompts which in case of
migraine shows that the self-reported occurrence of migraine among Finnish working aged
population in 2012 was 13%, being similar to rates observed in other studies. [1,15]  Female
majority and the observation of lower education level among migraineurs [16]  were corroborated
also in our cohort. It is known that the classification of a given primary headache disorder subtype
may change in a quarter of cases and the diagnostic certainty of other pain conditions may vary
significantly according to the doctor who made the diagnosis , e.g. general practitioners, other
specialists. [17]  Same limitation is true for musculoskeletal disorders in this and other studies
using recall prompts. However, self-reporting of migraine is considered reliable and the included
cases in this data had responded affirmatively to the inquiry on having migraine in all three
questionnaires up to 2012 which further improves the reliability. Moreover, the proportion of
migraineurs with prescribed triptans may be considered appropriate. [18]
A major strength of this study is the high response rates among migraineurs in the follow-up
questionnaires comprising altogether 1 505 included cases in 2012. Baseline characteristics in both
study groups were controlled for age and educational status. The possible differences in other
comorbidities than painful comorbidities are not expected to affect results and conclusions in our
study.  Exclusion of suspected 1% false negative migraine population according to triptan
prescription data do not interfere with the inferences in this study.
Limitations of the results and inferences based on the data may be the fairly low general response
rate in 1998 and the over presentation of older age groups. As migraine prevalence was not studied
here we find the response rate and number of cases adequate for the purposes in this study. The
sample size remained ample for statistical analyses to assess risk and occurrence of painful
comorbidities. However, given the careful non-response analysis after the baseline study, where
respondents and non-respondents were comparable with respect to the most important
demographic variables [13], we strongly assume that the conclusions drawn from the statistical
analyses may be considered reliable and random effects small. Also, the non-response analysis
showed only minor differences in physical health between participants and the general population.
[12,13]  That’s why results in this study may be generalizable in other migraine populations.
Association of migraine, painful musculoskeletal disorders and depression was shown in our
working aged cohort. The affective components in pain response are recognized in everyday
clinical practice and it may be argued that some of the pain syndromes under the study have a
predominantly psychological etiology, whereas others have a predominantly biological etiology.
Fibromyalgia was formerly classified as an inflammatory musculoskeletal disease but it is now
regarded as a condition where pain processing is dysfunctional [19], and similar to migraine [20]
both the ascending and descending pain pathways result in abnormal central amplification of pain
signals. Fibromyalgia, migraine and some musculoskeletal pain conditions carry an increased risk
for mood disorders and psychological distress [6, 21-23]  Inferences according to current data [6,
24]  suggest that in case of migraine there is an association with depression but the causal
direction of the relationship is unclear why it may be regarded as bidirectional.
The relative clinical and therapeutic implications in the complex relation of depression and painful
conditions are recognized in clinical practice. The currently used antidepressants, serotonin-
norepinephrine reuptake inhibitors (SNRI) and tricyclic antidepressants, treat both depression and
the painful conditions, such as migraine and fibromyalgia, by activating the central descending
inhibitory pain pathways and modulating pain transmission. [25,26]  These medications may be
the most promising agents for the modulation of pain symptoms, but their efficacy as headache
preventive varies widely. Tricyclic antidepressants are more effective than SNRIs in migraine
prophylaxis, but demonstrate dose-limiting side effects. [27,28]  The use of antidepressants in the
treatment of complex pain syndromes thus requires individual assessment. Assessment for the
need of efficacious and tolerated treatments is warranted as these disorders are shown to exert a
significant influence on working capacity [10,11] and health related quality of life (HRQol).
Subjects with migraine selected from the general population have been shown to have a lower
HRQol as measured by the SF-12 compared with the nonmigraine controls. [29]  The same is true
in fibromyalgia. [30]
Painful musculoskeletal comorbidities and depression associated to migraine as observed here
increase the disease burden and are expected to decrease the quality of life and productivity in
working aged population. Comorbidities should be taken into account when assessing the
therapeutic needs of a patient. As physiological mechanisms modulating pain expression are
further clarified in different age and gender groups, with and without comorbidities, improved
pharmacological interventions for pain syndromes are expected. The characterization of specific
pathophysiological changes underlying particular inflammatory diseases is set to produce
paradigms in pain management and future possibility of more specific diagnosis-based analgesic
medication, such as calcitonin gene related peptide (CGRP) receptor antagonist use in
migraine.[31]
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Figure 1. Flow chart of study population.
HeSSup data in 1998
Women  15,267
Men 10,628
Total       25,895
Responded to question on migraine
Women  15,161
Men         10,530
Total        25,691
Responded to question on migraine both in 1998 and 2003
Women  11,854
Men           7,382
Total 19,236
Responded to question on migraine in 1998, 2003 and 2012
Women     7,323
Men            4,273
Total       11,596
Responded affirmatively to question on
migraine in all inquiries = Migraine patients
Women 1,228
Men 277
Total       1,505
Responded negatively to question on
migraine in all inquiries
Women   4,638
Men        3,538
Total       8,176
Not having used triptans =
Controls
Women   4,581
Men         3,511
Total        8,092
Table 1. Demographic features of migraine patients and controls in the year 2012.
Migraine patients Controls
n % n % p-value
Gender <0.001
women 1228 81.6 4581 56.6
men 277 18.4 3511 43.4
Born on years <0.001
1944−1948 (age 64−68) 488 32.4 2602 32.2
1954−1958 (age 54−58) 440 29.2 2163 26.7
1964−1968 (age 44−48) 301 20.0 1680 20.8
1974−1978 (age 34−38) 276 18.3 1647 20.4
Marital status* 0.060
single, divorced or widowed 365 24.3 1874 23.3
married or cohabiting 1135 75.7 6185 76.7
Education* <0.001
lower 850 56.5 4370 54.1
higher** 655 43.5 3715 45.9
Beck’s depression inventory* <0.001
< 18 1377 92.7 7750 96.6
≥ 18 108 7.3 272 3.4
* All individuals did not respond to every question.
** At least matriculation examination.
Table 2. Proportion (%) of migraine patients and controls having reported painful musculoskeletal
disorders in the year 2012.
Migraine patients Controls
N=1494 N=8067
n % n  % p-value
Rheumatoid arthritis 67 4.5 212 2.6 <0.001
Osteoarthrosis 453 30.3 1587 19.7 <0.001
Sciatic syndrome 478 32.0 1503 18.6 <0.001
Fibromyalgia 91  6.1    165 2.0 <0.001
Table 3. Occurrence (%) of painful musculoskeletal disorders among old and young migraine patients and controls in the year 2012.
Age groups 54−58 and 64−68 Age groups 34−38 and 44−48
Women Men Women Men
Migraine Controls Migraine Controls Migraine Controls Migraine Controls
N = 744 N = 2521 N = 173 N = 2226 N = 474 N = 2047 N = 103 N = 1276
n % n  %  p-value n % n  %  p-value n  % n % p-value n % n % p-value
Rheumatoid arthritis 48 6.5 114  4.5  0.032 5 2.9 57  2.6 0.781 13 2.7 35 1.7 0.137 1 1.0 6 0.5 0.492
Osteoarthrosis 341  45.8 889  35.3  <0.001 50  28.9 485  21.8 0.030 53 11.2 140 6.8 0.001 9 8.7 73 5.7 0.213
Sciatic syndrome 285 38.3 558 22.1  <0.001 52 30.1 550 24.7 0.109 116 24.5 240   11.7  <0.001 25 24.3 155  12.2  <0.001
Fibromyalgia 57 7.7 111   4.4  <0.001 4 2.3 27 1.2 0.207 30 6.3 26 1.3 <0.001 0 0.0 1 0.1 0.777
Table 4. Summary of separate logistic regression analyses of migraine (ORs with 95% CI) for different painful musculoskeletal disorders.
Model 1 Model 2 Model 3 Model 4
Rheumatoid arthritis 1.74 (1.32 − 2.31) 1.46 (1.10 − 1.95) 1.44 (1.08 − 1.92) 1.43 (1.07 – 1.90)
Osteoarthrosis 1.78 (1.57 − 2.01) 1.58 (1.38 − 1.80) 1.57 (1.37 − 1.79) 1.52 (1.33 – 1.75)
Sciatic syndrome 2.06 (1.82 − 2.33) 2.09 (1.84 − 2.37) 2.07 (1.82 − 2.35) 2.00 (1.76 – 2.27)
Fibromyalgia 3.12 (2.40 − 4.06) 2.37 (1.81 − 3.09) 2.31 (1.77 − 3.02) 2.14 (1.63 – 2.82)
Model 1: Not adjusted
Model 2: Adjusted for age and gender
Model 3: Adjusted for age, gender and education
Model 4: Adjusted for age, gender, education and also for at least moderate depression (Beck > 18)
